Metabolic control of hospitalized diabetes mellitus patients: Application of standardised insulin protocols to hospitalized diabetes mellitus patients

ISRCTN ISRCTN82127342
DOI https://doi.org/10.1186/ISRCTN82127342
Secondary identifying numbers CIBH-1434
Submission date
16/08/2007
Registration date
03/09/2007
Last edited
03/09/2007
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Armando Villegas-Jimenez
Scientific

Direccion Medica
Vasco de Quiroga 15
Seccion XVI
Tlalpan
Mexico City
14000
Mexico

Phone +52 55 56 55 90 68
Email armandov@quetzal.innsz.mx

Study information

Study designSingle-centre, interventional, randomized, unblinded trial.
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Scientific title
Study acronymCOMETADIH
Study objectivesType 2 Diabetes Mellitus (DM2) is the leading cause of death and the most common diagnosis in hospitalized patients in Mexico. The economic burden that DM2 imposes to the public health system is onerous. Strategies focused on improving medical care and optimising resources are of paramount importance.

In-patient hyperglycemia negatively affects related comorbidities and has been linked to negative outcomes when compared to strategies that attain good glycemic control. Traditional insulin sliding scales are still widely used to treat in-patient hyperglycemia, even though this approach has been questioned and at present time is not considered good clinical practice. Novel strategies must be explored and compared to traditional insulin sliding scales.

Hypothesis of this study: Glycemic control of in-patients can be improved by the implementation of standardised insulin protocols. Glycemic control achieved by standardised insulin protocols will be better compared to traditional insulin sliding scales.
Ethics approval(s)The Human Biomedical Research Institutional Committee (an internal regulatory organisation for clinical research and ethics) approved this trial on June 10th, 2005 (ref: 1434).
Health condition(s) or problem(s) studiedType 2 Diabetes Mellitus
InterventionTwo general wards of a tertiary care hospital were randomly assigned to one of two standardised insulin protocols.

The two protocols consist of different proportions of intermediate and regular unmodified human insulin. One of the protocols was delivered in 4 daily injections and the other in 3. At initiation total daily insulin dose was calculated with the same guidelines for both protocols, further dose titration was provided according to pre-stablished glycemic goals and individual requirements.

Training was provieded to the nursing and medical staff and adherence to the protocol guidelines was supervised by the research team.

After inclusion to this study the patient was treated with the protocol assigned to the ward. Capillary Blood Glucose (CBG) was measured 4 times a day. Fasting Venous Blood Glucose (VBG) was measured according to the attending physician decision. All hypoglycemic episodes were registered in one of two categories:

1. Laboratory hypoglycemia (CBG <60 mg/dL)
2. Clinical hypoglycemia (Presence of adrenergic or neuroglycopenic symptoms with CBG >60 mg/dL that reverted after the ingestion of food)

Cause of the hypoglycemic episode was tracked and registered.

The patient was followed until discharge or until transfered to other areas such as the intensive care unit.

Glycemic control was compared in both protocols and, in a secondary analysis, the best protocol was compared with historical controls.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)insulin
Primary outcome measure1. Mean CBG during study period
2. Mean VBG during study period
3. Hypoglycemic episodes
Secondary outcome measures1. Clinical condition at the end of study period
2. Health team acceptance and adherence to the protocol guidelines
3. In-hospital morbidity and mortality registered during hospitalization
Overall study start date01/11/2005
Completion date30/05/2006

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participantsForty five patients on each protocol. Al teast ninety patients overall.
Key inclusion criteria1. Adult hospitalized patients of any age or gender
2. Diabetes mellitus (World Health Organization criteria) and uncontrolled hyperglycemia on admission (capillary blood glucose >200 mg/dL or HbA1c >7.0)
3. Signed informed consent
Key exclusion criteria1. Good glycemic control on oral medication
2. Refusal to participate
Date of first enrolment01/11/2005
Date of final enrolment30/05/2006

Locations

Countries of recruitment

  • Mexico

Study participating centre

Direccion Medica
Mexico City
14000
Mexico

Sponsor information

The National Institute of Medical Sciences and Nutrition (Mexico)
University/education

Vasco de Quiroga 15
Seccion XVI
Tlalpan
Mexico City
14000
Mexico

Phone +52 55 54 87 09 00
Email acabral@quetzal.innsz.mx
Website http://www.innsz.mx
ROR logo "ROR" https://ror.org/00xgvev73

Funders

Funder type

Other

This trial was funded by an unrestricted grant from institutional research budget of the National Institute of Medical Sciences and Nutrition (Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran). The National Institute of Medical Sciences and Nutrition is a non-profit organization, and its parental organizations are the Mexican Health Ministry (Secretaria de Salud de Mexico) and the Mexican National Autonomous University (Universidad Nacional Autonoma de Mexico). The National Institute of Medical Sciences and Nutrition is a tertiary care academic hospital.

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan